Search

Displaying results 1141 - 1150 of 7450 in total
  1. Drug

    Cerliponase alfa

    go.drugbank.com/drugs/DB13173
    ApprovedInvestigational

    [L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency.

  2. Drug

    Pyrimethamine

    go.drugbank.com/drugs/DB00205
    ApprovedInvestigationalVet approved

    One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.

    Mixtures: Rhobazin Plus Solution for Oral UseCategories: Antibiotics for Pneumocystis Pneumonia
  3. Drug

    Dexbrompheniramine

    go.drugbank.com/drugs/DB00405
    Approved

    Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.

    Categories: Antihistamines for Systemic Use
  4. Drug

    Isometheptene

    go.drugbank.com/drugs/DB06706
    Approved

    It is used for treating migraines and tension headaches.

    Categories: Drugs for Functional Gastrointestinal Disorders
  5. Drug

    Trioxsalen

    go.drugbank.com/drugs/DB04571
    ApprovedWithdrawn

    It is administered either topically or orally in conjunction with UV-A (the least damaging form of ultraviolet light) for phototherapy treatment of vitiligo and hand eczema. … In research it can be conjugated to dyes for confocal microscopy and used to visualize sites of DNA damage.[3] The compound is has been explored for development of antisense oligonucleotides that can be

    Categories: Antipsoriatics for Systemic Use, Antipsoriatics for Topical Use
  6. Drug

    Telaprevir

    go.drugbank.com/drugs/DB05521
    ApprovedWithdrawn

    HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. … of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    Glucarpidase

    go.drugbank.com/drugs/DB08898
    ApprovedInvestigational

    for therapeutic purposes. … In 1983, the gene for carboxypeptidase G2, or glucarpidase, was derived from _Pseudomonas_ sp. strain RS-16 to be cloned into _Escherichia coli_, allowing the enzyme to be produced in sufficient quantities

    Categories: Detoxifying Agents for Antineoplastic Treatment
  8. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    [L50627] Non-muscle invasive bladder cancer (NMIBC), which accounts for 75% of all bladder tumours, is commonly treated with transurethral resection of the bladder tumour and Bacillus Calmette-Guérin ( … [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without

  9. Drug

    Loracarbef

    go.drugbank.com/drugs/DB00447
    ApprovedWithdrawn

    Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. … of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause

    Categories: Antivirals for Systemic Use, Treatments for Hepatitis C